Canopy Growth (NASDAQ:CGC) Stock Price Down 3.8% – Here’s What Happened

Canopy Growth Corporation (NASDAQ:CGC) shares fell 3.8% during trading on Friday . The company traded as low as $1.63 and last traded at $1.6250. 13,981,633 shares traded hands during mid-day trading, a decline of 18% from the average session volume of 17,032,730 shares. The stock had previously closed at $1.69.

More Canopy Growth News

Here are the key news stories impacting Canopy Growth this week:

• Positive Sentiment: Trump signed an executive order to reclassify marijuana toward Schedule III, which could reduce regulatory friction, improve banking/insurance access and broaden research and CBD availability — a major structural positive for cannabis companies. President Trump Signs Cannabis Executive Order: Canopy Growth Collapses
• Positive Sentiment: Mainstream outlets emphasize the policy shift as near-term sentiment fuel for the sector — easier federal research, potential tax and regulatory relief and improved consumer access. (Multiple coverage: CNBC, Reuters, Business Insider, Zacks). Trump signs executive order reclassifying pot, opening door to broader access
• Positive Sentiment: Zacks and analyst commentary note rescheduling to Schedule III could reshape regulation and taxation for the sector, boosting long-term earnings potential for well-positioned firms. Trump Orders Marijuana Reclassification: What It Means for the Sector
• Positive Sentiment: Roth MKM reiterated a buy rating on Canopy Growth — supporting a bullish analyst view even after recent gains. That may limit downside for longer-term investors. Roth MKM Sticks to Their Buy Rating for Canopy Growth (CGC)
• Positive Sentiment: Several analyst pieces and investor write-ups highlight upside after the rally, with some calling for further gains — evidence of continuing bullish consensus despite volatility. Canopy Growth Is Surging and Analysts Still Think It Can Gain 40% from Here
• Neutral Sentiment: Coverage explaining consumer implications and CBD access is informative but ambiguous in timing — benefits are structural but may take months to implement through the DOJ and FDA. Trump moves to ease cannabis restrictions – what does it mean for consumers?
• Negative Sentiment: Despite the sector-positive headlines, some outlets highlight an immediate sell-off in Canopy shares — investors likely took profits after a big run, rotated to U.S. operators who may gain more from rescheduling, and reacted to CGC’s still-weak profitability metrics. High trading volume reinforces that this was active rebalancing rather than a one-off trade. President Trump Signs Cannabis Executive Order: Canopy Growth Collapses

Analyst Ratings Changes

CGC has been the topic of several recent analyst reports. Benchmark upgraded shares of Canopy Growth from a “sell” rating to a “hold” rating in a research note on Monday, November 10th. Alliance Global Partners restated a “neutral” rating on shares of Canopy Growth in a report on Monday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Canopy Growth in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Canopy Growth from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Three equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Reduce”.

Canopy Growth Stock Down 9.2%

The business’s fifty day moving average price is $1.26 and its 200 day moving average price is $1.31. The firm has a market capitalization of $565.58 million, a price-to-earnings ratio of -0.80 and a beta of 0.40. The company has a current ratio of 5.50, a quick ratio of 4.23 and a debt-to-equity ratio of 0.31.

Canopy Growth (NASDAQ:CGC) last issued its quarterly earnings results on Friday, November 7th. The company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.10. The firm had revenue of $47.86 million during the quarter, compared to analysts’ expectations of $71.82 million. Canopy Growth had a negative net margin of 113.21% and a negative return on equity of 61.97%. On average, equities analysts expect that Canopy Growth Corporation will post -2.81 EPS for the current year.

Insider Activity

In related news, CEO Luc Mongeau purchased 27,469 shares of the company’s stock in a transaction that occurred on Monday, September 22nd. The shares were purchased at an average price of $1.82 per share, for a total transaction of $49,993.58. Following the transaction, the chief executive officer directly owned 812,368 shares of the company’s stock, valued at approximately $1,478,509.76. The trade was a 3.50% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold a total of 23,075 shares of company stock worth $36,459 over the last 90 days. Company insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Boothbay Fund Management LLC purchased a new stake in shares of Canopy Growth during the second quarter worth approximately $30,000. Midwest Trust Co acquired a new position in Canopy Growth in the 3rd quarter valued at $31,000. Wealth Enhancement Advisory Services LLC raised its position in Canopy Growth by 81.3% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 32,336 shares of the company’s stock worth $41,000 after buying an additional 14,498 shares during the last quarter. Genesee Capital Advisors LLC lifted its stake in shares of Canopy Growth by 166.1% in the 3rd quarter. Genesee Capital Advisors LLC now owns 40,047 shares of the company’s stock worth $58,000 after acquiring an additional 25,000 shares during the period. Finally, Insigneo Advisory Services LLC increased its stake in shares of Canopy Growth by 168.7% during the third quarter. Insigneo Advisory Services LLC now owns 43,001 shares of the company’s stock worth $63,000 after acquiring an additional 27,000 shares during the period. 3.33% of the stock is currently owned by hedge funds and other institutional investors.

About Canopy Growth

Canopy Growth Corporation is a leading Canadian cannabis company engaged in the production, distribution and sale of both medical and recreational cannabis products. Headquartered in Smiths Falls, Ontario, the company cultivates a diversified portfolio of offerings that includes dried flower, pre-rolled joints, oils, softgel capsules and edibles. Canopy Growth also markets derivative products such as beverages and wellness formulations under a range of brands, aiming to serve both patient and adult-use markets.

The company operates through multiple subsidiaries, including Tweed Inc, Spectrum Therapeutics and Tokyo Smoke, each targeting distinct consumer segments.